

Christian Barro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6126011/publications.pdf>

Version: 2024-02-01

67
papers

7,556
citations

116194

36
h-index

116156

66
g-index

68
all docs

68
docs citations

68
times ranked

6830
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. <i>Multiple Sclerosis Journal</i> , 2022, 28, 573-582.	1.4	17
2	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	2.8	21
3	Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732110693.	0.5	3
4	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 220-231.	1.4	55
5	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 52-60.	1.4	41
6	Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003). <i>Brain and Behavior</i> , 2021, 11, e01998.	1.0	3
7	Quantification of the Neurofilament Light Chain Protein by Single Molecule Array (Simoa) Assay. <i>Neuromethods</i> , 2021, , 223-233.	0.2	0
8	Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance. <i>Human Brain Mapping</i> , 2021, 42, 2399-2415.	1.9	10
9	Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2014-2022.	1.4	28
10	Neurological symptoms and blood neurofilament light levels. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 13-20.	1.0	12
11	Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum. <i>Frontiers in Neurology</i> , 2021, 12, 691683.	1.1	3
12	Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. <i>Journal of Psychiatric Research</i> , 2021, 140, 141-148.	1.5	36
13	Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort. <i>European Journal of Neurology</i> , 2021, 28, 4153-4166.	1.7	10
14	The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases. <i>Journal of Neuroscience Methods</i> , 2021, 361, 109281.	1.3	14
15	Fingolimod in children with Rett syndrome: the FINGORETT study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 19.	1.2	12
16	Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. <i>Multiple Sclerosis Journal</i> , 2020, 26, 210-219.	1.4	105
17	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1670-1681.	1.4	61
18	Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 58.	4.5	135

#	ARTICLE	IF	CITATIONS
19	Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1691-1699.	1.4	67
20	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102534.	0.9	14
21	Blood neurofilament light: a critical review of its application to neurologic disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2508-2523.	1.7	132
22	Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	43
23	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. <i>Neurology</i> , 2020, 94, e2457-e2467.	1.5	61
24	Growth differentiation factor 15 is increased in stable MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	12
25	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. <i>EMBO Molecular Medicine</i> , 2020, 12, e11803.	3.3	73
26	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. <i>Neurology</i> , 2020, 94, e1201-e1212.	1.5	88
27	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. <i>Neurology</i> , 2020, 94, e1950-e1960.	1.5	45
28	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	24
29	NfL and pNfH are increased in Friedreich's ataxia. <i>Journal of Neurology</i> , 2020, 267, 1420-1430.	1.8	17
30	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. <i>Nature Communications</i> , 2020, 11, 812.	5.8	316
31	Serum neurofilament light chain and optical coherence tomography measures in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	22
32	Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease. <i>Journal of Stroke</i> , 2020, 22, 369-376.	1.4	27
33	Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1669-1677.	2.4	27
34	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. <i>JAMA Neurology</i> , 2019, 76, 1359.	4.5	129
35	Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy. <i>Epilepsy and Behavior</i> , 2019, 101, 106432.	0.9	15
36	Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1757-1770.	1.7	66

#	ARTICLE	IF	CITATIONS
37	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1556-1564.	1.4	32
38	Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. <i>Neurology</i> , 2019, 93, e968-e974.	1.5	29
39	Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort – a prospective cohort study. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 403.	0.9	6
40	Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. <i>Neurology</i> , 2019, 93, e1299-e1311.	1.5	129
41	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	15.2	610
42	Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1081-1089.	1.7	43
43	Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. <i>European Journal of Neurology</i> , 2019, 26, 1200-1204.	1.7	17
44	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 187-194.	1.4	59
45	Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. <i>Neurology</i> , 2019, 92, e1007-e1015.	1.5	346
46	Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 678-686.	1.4	148
47	Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. <i>Hypertension</i> , 2018, 71, 1178-1184.	1.3	29
48	Serum neurofilament light chain in patients with acute cerebrovascular events. <i>European Journal of Neurology</i> , 2018, 25, 562-568.	1.7	70
49	Neurofilament light chain predicts disease activity in relapsing-remitting MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e422.	3.1	107
50	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. <i>Neurology</i> , 2018, 90, e22-e30.	1.5	148
51	Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury. <i>Frontiers in Neurology</i> , 2018, 9, 984.	1.1	16
52	Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1478-1491.	1.7	115
53	Serum neurofilament light. <i>Neurology</i> , 2018, 91, e1338-e1347.	1.5	137
54	NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. <i>Neurology</i> , 2018, 91, 755-757.	1.5	11

#	ARTICLE	IF	CITATIONS
55	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 577-589.	4.9	1,177
56	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. <i>Brain</i> , 2018, 141, 2382-2391.	3.7	345
57	Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1093-1094.	0.5	48
58	Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden. <i>Journal of Stroke</i> , 2018, 20, 228-238.	1.4	82
59	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. <i>Neurology</i> , 2017, 88, 826-831.	1.5	168
60	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 81, 857-870.	2.8	768
61	Serum neurofilament light is sensitive to active cerebral small vessel disease. <i>Neurology</i> , 2017, 89, 2108-2114.	1.5	139
62	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1600-1613.	1.4	28
63	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1270-1272.	0.9	65
64	Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1655-1661.	1.4	517
65	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 623-636.	1.7	207
66	Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1550-1559.	1.4	202
67	Neurofilament Light Chain Determination from Peripheral Blood Samples. <i>Methods in Molecular Biology</i> , 2015, 1304, 93-98.	0.4	12